Tradestie Institutional Equity Comparison Engine
DMAC vs FENC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FENC Overall Edge
FENC Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Fennec Pharmaceuticals Inc. Common Stock (FENC) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FENC at 11.2x Forward P/E and 5.6% operating margin (+57.3% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against FENC sits in BREAKOUT (24th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
FENC
DMAC N/M vs FENC 11.2x Fwd P/E
Growth & Margin Winner
FENC
Op Margin 0.0% vs 5.6% ยท YoY +0.0% vs +57.3%
Momentum & Technical Winner
FENC
1Y +55.3% vs +56.0% ยท 52W Pos 55% vs 84%
Options & Structure Winner
FENC
SURGE (14th %ile IV) vs BREAKOUT (24th %ile IV)
DMAC
NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap
$503.1M
1M Return
+11.16%
1Y Return
+55.26%
Forward P/E
N/M
Unified AI Score
46.3 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
FENC
NASDAQ
Fennec Pharmaceuticals Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$12.00
+3.27% 1D
Market Cap
$405.7M
1M Return
+20.24%
1Y Return
+56.05%
Forward P/E
11.2x
Unified AI Score
44.2 / 100
HOLD
Tech 15.0
Fund 49.0
Flow 74.0
Mom 74.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DMAC +55.26%
FENC +56.05%
Spread: +0.79 pp (FENC Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | FENC Revenue | DMAC Op. Margin | FENC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -1352.2% | N/A | DMAC |
| FY2020 | N/A | $0M | N/A | -10520.6% | FENC |
| FY2022 | N/A | $0M | N/A | -1471.6% | FENC |
| FY2023 | N/A | $20M | N/A | -60.1% | FENC |
| FY2024 | N/A | $50M | N/A | 5.4% | FENC |
| FY2025 | N/A | $40M | N/A | -14.1% | FENC |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DMAC | FENC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $503.1M | $405.7M | Larger Scale | DMAC |
| Trailing P/E Ratio Valuation | N/M | 12.6x | Lower Multiple | FENC |
| Forward P/E Ratio Valuation | N/M | 11.2x | Lower Multiple | FENC |
| Revenue Growth (YoY) Growth | +0.0% | +57.3% | Higher Growth | FENC |
| Operating Margin (TTM) Profitability | 0.0% | 5.6% | Higher Margin | FENC |
| Net Profit Margin Profitability | 0.0% | 3.0% | Higher Margin | FENC |
| Return on Equity (ROE) Capital Efficiency | -114.6% | 9.1% | Higher ROE | FENC |
| 52-Week Range Position Momentum | 55% ($5โ$11) | 84% ($6โ$13) | Stronger Trend | FENC |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 98% Vol | 1.71ฮฒ ยท 69% Vol | Lower Realized Risk | FENC |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 44.2 / 100 (HOLD) | Higher Composite | DMAC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DMAC vs FENC Buy Guide
DMAC
SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
FENC
BREAKOUT
98d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
24th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DMAC nor FENC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.